Skip to main content

Table 3 Characteristics of patients who met 80/80/80 rule and were candidate for propensity score matching

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Patients who met

Total

PEG-IFN alfa-2a

PEG-IFN alfa- 2b

P*

80/80/80 rule

    

Genotype 1, n (%)

286

171 (59.8)

115 (40.2)

0.45

 Age, years

49 ± 11

48 ± 11

49 ± 11

0.52

 BMI (Kg/m2)

24.6 ± 3.1

24.8 ± 3.2

24.3 ± 2.9

0.29

 ALT (IU/L)

100 ± 81

103 ± 80

97 ± 84

0.51

 HCV RNA (IU/mL)

3.7×106±1.6×106

2.4×106±1.5×106

5.6×106±2.2×106

0.15

 F3-4 Fibrosis stage, n (%) §

29/94 (30.9)

26/75 (34.7)

3/19 (15.8)

0.17

Genotype 2/3, n (%)

185

107 (57.8)

78 (42.2)

 

 Age, years

49 ± 12

48 ± 12

50 ± 11

0.16

 BMI (Kg/m2)

23.9 ± 2.7

24.3 ± 3.1

23.6 ± 2.4

0.16

 ALT (IU/L)

97 ± 94

101 ± 88

94 ± 88

0.51

 HCV RNA (IU/mL)

1.8×106±1.5×106

1.6×106±1.2×106

2.1×106±1.4×106

0.49

 F3-4 Fibrosis stage, n (%)

11/63 (17.5)

7/51 (13.7)

4/12 (33.3)

0.19

Genotype others, n (%)

9 (1.9)

6 (2.1)

3 (1.5)

 

Propensity score matched patients

Total

PEG-IFN alfa-2a

PEG-IFN alfa- 2b

P*

Genotype 1, n (%)

248

124

124

0.45

 Age, years

50 ± 11

51 ± 11

50 ± 11

0.43

 Gender (male), n (%)

148 (59.7)

112 (65.5)

74 (64.3)

0.90

 BMI (Kg/m2)

24.4 ± 3.2

24.7 ± 3.2

24.3 ± 3.3

0.38

 ALT (IU/L)

93 ± 76

95 ± 74

92 ± 79

0.83

 HCV RNA (IU/mL)

3.0×106±1.3×106

2.5×106±1.3×106

3.6×106±1.1×106

0.31

 F3-4 Fibrosis stage, n (%) #

22/73 (30.1)

18/50 (36.0)

4/23 (18.2)

0.17

Genotype 2/3, n (%)

150

75

75

 

 Age, years

50 ± 11

48 ± 12

50 ± 11

0.16

 Gender (male), n (%)

81 (54.0)

162 (61.8)

108 (62.1)

0.96

 BMI (Kg/m2)

23.9 ± 2.9

24.3 ± 3.1

23.6 ± 2.4

0.16

 ALT (IU/L)

89 ± 76

101 ± 88

94 ± 88

0.51

 HCV RNA (IU/mL)

1.7×106±1.4×106

1.6×106±1.2×106

2.1×106±1.4×106

0.49

F3-4 Fibrosis stage, n (%)§

10/46 (21.7)

6/34 (17.6)

4/12 (33.3)

0.42

  1. Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon.
  2. *P-value for difference between the PEG-IFN alfa-2a and PEG-IFN alfa-2b groups.
  3. mean ± standard deviation.
  4. §, ‡ Data were available only in 94 and 63 patients, respectively.
  5. #,¥Data were available only in 73 and 46 patients, respectively. If the number of patients was smaller than 5, Fisher’s exact test was used.